⌘K

Home/Filings/4/0001104659-22-012870

4//SEC Filing

Kruse Bo 4

Accession 0001104659-22-012870

CIK 0001722964other

View on SEC.gov Company Profile

Filed

Feb 6, 7:00 PM ET

Accepted

Feb 7, 5:16 PM ET

Size

4.7 KB

Accession

0001104659-22-012870

Insider Transaction Report

Form 4

Period: 2022-02-04

Y-mAbs Therapeutics, Inc.YMAB

DirectorEVP, CFO, Secy & Treas.

Transactions

Sale
Common Stock
2022-02-04$7.97/sh−4,000$31,880→ 185,077 total

Footnotes (1)

[F1]Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2021.

Documents

1 file

4
tm225222-3_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Y-mAbs Therapeutics, Inc.

CIK 0001722964

Entity typeother

Related Parties

1

filerCIK 0001752940

Filing Metadata

Form type: 4
Filed: Feb 6, 7:00 PM ET
Accepted: Feb 7, 5:16 PM ET
Size: 4.7 KB

View on SEC.gov